Bard Access loses out on Carmel Pharma

Quote

Anonymous

Guest
It must be a tough day for Bard Access when they lose out on the Phaseal (Carmel Pharma) deal to BD. The rumor on the street is Bard was in the final stages of closing the deal before they lost out to BD. They can't grow their business unless it is through acquisitions! Just listen to CR Bard's last earnings call. Their existing products are flat (can you say commodities?) and when they lose out on acquisitons, where is their growth going to come from?
 












The facts are facts. Call me what you want. If it weren't for Bard Peripheral led acquisitions, there would be no growth. How does BD beat Bard to a key acquisition like Carmel Pharma? Hahahahaha! Now tell me, who is the real idiot? Hahahahaha!
 






Anonymous said:
The facts are facts. Call me what you want. If it weren't for Bard Peripheral led acquisitions, there would be no growth. How does BD beat Bard to a key acquisition like Carmel Pharma? Hahahahaha! Now tell me, who is the real idiot? Hahahahaha!
Click to expand...

I agree. lets see if the stock falls even further. B&D is laughing at you now. Ha Ha Ha Ha!
 






Is this the "big acquisition" that management has been telling us reps was around the corner? Are you fucking kidding me? Just what Bard Access needs: another tube and syringe. Without this "key" acquisition, 2012 is going to be another superb year.
 


















Not so...bard access systems just announced layoffs. Hemink and Jiaye Zhou are leading the way! What pathetic losers. Lining their pocket with bonuses and asking for voluntary layoffs. Management courage redefined.
 






Come on now, Bard Access has had a string of unbelievably impressive acquisitions: Spire to enhance their dialysis footprint only to pull the majority of worthwhile products off the market. Site-Scrub end cap cleaners that they can't seem to figure out how to get CHG to work in, so it becomes the world's most expensive alcohol swab. Sapiens that they were forced to buy because their internally developed device Sherlock 3CG couldn't cut it and let's not forget about all the success they've had acquiring catheter coatings...they might as well change their BD department to their BS department since the aforementioned moves are clearly "business stagnation" projects.
 






Anonymous said:
Come on now, Bard Access has had a string of unbelievably impressive acquisitions: Spire to enhance their dialysis footprint only to pull the majority of worthwhile products off the market. Site-Scrub end cap cleaners that they can't seem to figure out how to get CHG to work in, so it becomes the world's most expensive alcohol swab. Sapiens that they were forced to buy because their internally developed device Sherlock 3CG couldn't cut it and let's not forget about all the success they've had acquiring catheter coatings...they might as well change their BD department to their BS department since the aforementioned moves are clearly "business stagnation" projects.
Click to expand...

You are completely correct. Man I wish I worked for Medcomp. Now there's innovation.
 






Medcomp's strategic goal is to imitate and undercut on price. They don't give a rat's ass about innovation, so their doing just fine for themselves as Bard tries to charge hospitals $300 for a Sapiens-ready triple lumen PICC in a max barrier packaging configuration. Their so-called "innovation" has completely priced them out of a cost-sensitive market segment since we are talking about a disposable commodity here.

My guess is Medcomp is quite pleased with Bard continuing to "innovate" and shoot themselves in the foot with overpriced, underperforming technologies. Good call, Sherlock.
 












Anonymous said:
Medcomp's strategic goal is to imitate and undercut on price. They don't give a rat's ass about innovation, so their doing just fine for themselves as Bard tries to charge hospitals $300 for a Sapiens-ready triple lumen PICC in a max barrier packaging configuration. Their so-called "innovation" has completely priced them out of a cost-sensitive market segment since we are talking about a disposable commodity here.

My guess is Medcomp is quite pleased with Bard continuing to "innovate" and shoot themselves in the foot with overpriced, underperforming technologies. Good call, Sherlock.
Click to expand...

Oh, I stand corrected then. Thanks for your guess.
 






Anonymous said:
Not so...bard access systems just announced layoffs. Hemink and Jiaye Zhou are leading the way! What pathetic losers. Lining their pocket with bonuses and asking for voluntary layoffs. Management courage redefined.
Click to expand...

Well its been almost 6 months since the Carmel acquisition... god BD is awful. absolutely a large pharma company without the pills.. B O H I C A... bend over here it comes again!
 






Re: Bard Access loses out on Carmel Pharma to BD

Well,

I have been here at BD now since the acquisition of Carmel Pharma, and let me be the first to tell you that BD stands for Big Disaster. I have never been with a company that has been less interested in their employees than the reports they have to do. The formal managers with Carmel are no more than puppets and/or ostriches with their heads stuck in the sand... All anyone like Doug Parish or his cronies care about is a lame funnel report. Also, what kind of organization hands out quotas 6 months into the fiscal year.... Can we say pink slips for PhaSeal reps???

The other thing that is lame is that this sorry division we were put in 'MSS',is sub par at best. All these reps do is try and piggyback on us trying to sell our product and claiming the sell in their respective territories instead of working with us to help each other. Big Disaster is known for letting people go in September because it is the end of their fiscal year and I will be shocked if they keep all the PhaSeal reps at the end of September...
 


















Top Bottom
Back
Quote